Please login to the form below

Deal Watch table for January 2015

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.

For an indepth analysis of these deals, read 'Pharma deals during January 2015'

Licensor acquired / licensee acquirer	Product / technology	Deal type	Headline ($m)
NPS/Shire	NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome	Corporate acquisition	5,200
Foundation Medicine/Roche	Broad R&D collaboration to optimise oncology treatments via Foundations genomic analysis and molecular information	Majority interest acquisition	1,180
Kite Pharma/Amgen	Chimeric Antigen Receptor (CAR) T cell immunotherapy engineered autologous cell therapy (eACT) platform, Amgen contribute cancer targets	Licence collaboration agreement	1,110
Janssen/ Depomed	Nucynta [tapentadol] franchise including extended release tablets and oral solutions	Divestment of US rights	1,050
Esteve/ Mundipharma	Discovery and development of next generation pain products including E-52862 in P2 for neuropathic pain	Strategic collaboration	1,000
Isis/ Janssen	Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes)	Collaboration to discover and develop candidates	835
Fedora and Meiji Seika/Roche	Roche secures rights to OP0595 a beta lactamase inhibitor in P1 clinical development against multi drug resistant bacteria	Licence agreement	750
Convergence/Biogen Idec	Includes a neuropathic pain portfolio with CNV 1014802 in P2 for trigeminal neuralgia	Corporate acquisition	675
Trophos/Roche	Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury	Corporate acquisition	545
Cytos Biotechnology/ OnCore	Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases	Exclusive licence	522
AC Immune/ Janssen	To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease	3 year research collaboration and exclusive licence	509
Neuropore Therapies/UCB	To develop and commercialise NPT200-11 and other therapeutic products for Parkinson's disease	Collaboration agreement	480
PneumRx/BTG	Includes RePneu a coil to open airways in emphysema patients	Corporate acquisition	475
Phenex/Gilead	Small molecules targeting FXR Farnesoid X receptor (FXR) programme Px102, Px104 in P2 development in Non-Alcoholic Steatohepatitis [NASH]	Asset acquisition	470
Auden Mckenzie/Actavis	Purchase includes generic portfolio of 175 products making Actavis no 1 generic supplier in the UK	Corporate acquisition	458
Agenus/Incyte	Using Agenus' antibody discovery platform focusing on 4 checkpoint modulator programmes includes $35m equity	Licence to develop and commercialise	410
Aurigene /Curis	2 programmes including IRAK4 Inhibitors and small molecule antagonist of programmed death [PD-L1]	Collaboration and option to a licence	346
Vedanta /J&J	Microbiome-based drug candidate VE202 for bowel diseases, Crohn's disease and ulcerative colitis	Licence to develop anti-bacterial VE202	241
OnCyte/Cardio3	Acquisition of the oncology division of Celdara Medical including CM-CS1 an autologous CAR-T cell drug candidate which uses NKG2D to target tumour antigens	Asset acquisition	180
ZymeWorks/Celgene	Development of multiple bi-specific antibodies using the Azymetric platform	Licence, option and collaboration	164
Novartis/Aspen	Purchase of the heparin based anticoagulant Mono-Embolex, with sales of €68m in 2013	Asset acquisition	142
Amunix/Naia	To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel syndrome	2 exclusive licences	140